EA016038B1 - Антитело к tgf-бета и его применение - Google Patents

Info

Publication number

EA016038B1

EA016038B1 EA200702278A EA200702278A EA016038B1 EA 016038 B1 EA016038 B1 EA 016038B1 EA 200702278 A EA200702278 A EA 200702278A EA 200702278 A EA200702278 A EA 200702278A EA 016038 B1 EA016038 B1 EA 016038B1

Authority

EA

Eurasian Patent Office

Prior art keywords

beta

antibody

amino acid

binding

acid sequence

Prior art date

2005-04-22

Links

• Espacenet
• Global Dossier
• Discuss

• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title abstract description 7
• 238000009739 binding Methods 0.000 claims abstract description 277
• 230000027455 binding Effects 0.000 claims abstract description 276
• 239000012634 fragment Substances 0.000 claims abstract description 124
• 239000000427 antigen Substances 0.000 claims abstract description 71
• 108091007433 antigens Proteins 0.000 claims abstract description 71
• 102000036639 antigens Human genes 0.000 claims abstract description 71
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 60
• 201000010099 disease Diseases 0.000 claims abstract description 39
• 238000011282 treatment Methods 0.000 claims abstract description 37
• 208000020832 chronic kidney disease Diseases 0.000 claims abstract description 27
• 239000003814 drug Substances 0.000 claims abstract description 25
• 230000003176 fibrotic effect Effects 0.000 claims abstract description 12
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 79
• 206010028980 Neoplasm Diseases 0.000 claims description 42
• 238000004519 manufacturing process Methods 0.000 claims description 20
• 229910052698 phosphorus Inorganic materials 0.000 claims description 15
• 201000011510 cancer Diseases 0.000 claims description 14
• 241000282412 Homo Species 0.000 claims description 11
• 229940079593 drug Drugs 0.000 claims description 11
• 229910052739 hydrogen Inorganic materials 0.000 claims description 11
• 229910052796 boron Inorganic materials 0.000 claims description 9
• 239000003937 drug carrier Substances 0.000 claims description 9
• 229910052757 nitrogen Inorganic materials 0.000 claims description 9
• 229910052720 vanadium Inorganic materials 0.000 claims description 8
• 230000009260 cross reactivity Effects 0.000 claims description 6
• 239000008194 pharmaceutical composition Substances 0.000 claims description 5
• 229910052760 oxygen Inorganic materials 0.000 claims description 4
• 239000005541 ACE inhibitor Substances 0.000 claims description 3
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 3
• 238000002648 combination therapy Methods 0.000 claims 2
• 101000709238 Homo sapiens Serine/threonine-protein kinase SIK1 Proteins 0.000 claims 1
• 101000709250 Homo sapiens Serine/threonine-protein kinase SIK2 Proteins 0.000 claims 1
• 102100032771 Serine/threonine-protein kinase SIK1 Human genes 0.000 claims 1
• 102100034377 Serine/threonine-protein kinase SIK2 Human genes 0.000 claims 1
• 239000000203 mixture Substances 0.000 abstract description 230
• 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract description 8
• 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract description 8
• 208000008839 Kidney Neoplasms Diseases 0.000 abstract 1
• 206010038389 Renal cancer Diseases 0.000 abstract 1
• 201000010982 kidney cancer Diseases 0.000 abstract 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 533
• 108090000623 proteins and genes Proteins 0.000 description 125
• 108090000765 processed proteins & peptides Proteins 0.000 description 118
• 102000004169 proteins and genes Human genes 0.000 description 114
• 102000004196 processed proteins & peptides Human genes 0.000 description 109
• 235000018102 proteins Nutrition 0.000 description 109
• 238000010276 construction Methods 0.000 description 107
• 229920001184 polypeptide Polymers 0.000 description 107
• 238000000034 method Methods 0.000 description 96
• 210000004027 cell Anatomy 0.000 description 94
• 235000001014 amino acid Nutrition 0.000 description 74
• 229940024606 amino acid Drugs 0.000 description 65
• 150000001413 amino acids Chemical class 0.000 description 60
• 230000014509 gene expression Effects 0.000 description 38
• 238000004458 analytical method Methods 0.000 description 32
• 230000000694 effects Effects 0.000 description 32
• 239000000243 solution Substances 0.000 description 31
• 230000015572 biosynthetic process Effects 0.000 description 30
• 238000003018 immunoassay Methods 0.000 description 30
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 28
• 238000003556 assay Methods 0.000 description 27
• 238000006467 substitution reaction Methods 0.000 description 26
• 206010016654 Fibrosis Diseases 0.000 description 24
• 230000004761 fibrosis Effects 0.000 description 23
• 238000002347 injection Methods 0.000 description 22
• 239000007924 injection Substances 0.000 description 22
• 230000021736 acetylation Effects 0.000 description 21
• 238000006640 acetylation reaction Methods 0.000 description 21
• 208000035475 disorder Diseases 0.000 description 21
• 102000040430 polynucleotide Human genes 0.000 description 21
• 108091033319 polynucleotide Proteins 0.000 description 21
• 239000002157 polynucleotide Substances 0.000 description 21
• 125000000539 amino acid group Chemical group 0.000 description 20
• 241001465754 Metazoa Species 0.000 description 19
• 238000006243 chemical reaction Methods 0.000 description 18
• 230000009870 specific binding Effects 0.000 description 18
• 238000010494 dissociation reaction Methods 0.000 description 17
• 230000005593 dissociations Effects 0.000 description 17
• 108020001507 fusion proteins Proteins 0.000 description 17
• 102000037865 fusion proteins Human genes 0.000 description 17
• 108060003951 Immunoglobulin Proteins 0.000 description 16
• 101100460719 Mus musculus Noto gene Proteins 0.000 description 16
• DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 16
• 101100187345 Xenopus laevis noto gene Proteins 0.000 description 16
• 102000018358 immunoglobulin Human genes 0.000 description 16
• 230000001965 increasing effect Effects 0.000 description 16
• 108020003175 receptors Proteins 0.000 description 16
• 102000005962 receptors Human genes 0.000 description 16
• 239000000523 sample Substances 0.000 description 16
• 239000013598 vector Substances 0.000 description 16
• 239000013604 expression vector Substances 0.000 description 15
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
• 235000013350 formula milk Nutrition 0.000 description 14
• 239000000463 material Substances 0.000 description 14
• 238000012360 testing method Methods 0.000 description 14
• 206010018364 Glomerulonephritis Diseases 0.000 description 13
• 241000700159 Rattus Species 0.000 description 13
• 239000000872 buffer Substances 0.000 description 13
• 230000006378 damage Effects 0.000 description 13
• 238000011534 incubation Methods 0.000 description 13
• 208000011580 syndromic disease Diseases 0.000 description 13
• FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 12
• 241000699666 Mus <mouse, genus> Species 0.000 description 12
• 239000003153 chemical reaction reagent Substances 0.000 description 12
• 150000001875 compounds Chemical class 0.000 description 12
• 230000007423 decrease Effects 0.000 description 12
• 230000000670 limiting effect Effects 0.000 description 12
• 239000000126 substance Substances 0.000 description 12
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 11
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 11
• 108010029485 Protein Isoforms Proteins 0.000 description 11
• 102000001708 Protein Isoforms Human genes 0.000 description 11
• 230000000903 blocking effect Effects 0.000 description 11
• 230000001684 chronic effect Effects 0.000 description 11
• 230000000875 corresponding effect Effects 0.000 description 11
• 210000004602 germ cell Anatomy 0.000 description 11
• 230000005764 inhibitory process Effects 0.000 description 11
• 210000004185 liver Anatomy 0.000 description 11
• 230000035755 proliferation Effects 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
• 206010027476 Metastases Diseases 0.000 description 10
• 238000007792 addition Methods 0.000 description 10
• 230000033115 angiogenesis Effects 0.000 description 10
• 230000004071 biological effect Effects 0.000 description 10
• 230000004663 cell proliferation Effects 0.000 description 10
• 239000003795 chemical substances by application Substances 0.000 description 10
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 10
• 238000001514 detection method Methods 0.000 description 10
• 238000011161 development Methods 0.000 description 10
• 230000018109 developmental process Effects 0.000 description 10
• 210000002744 extracellular matrix Anatomy 0.000 description 10
• 230000001976 improved effect Effects 0.000 description 10
• 210000003734 kidney Anatomy 0.000 description 10
• 239000003446 ligand Substances 0.000 description 10
• 238000005259 measurement Methods 0.000 description 10
• 230000003472 neutralizing effect Effects 0.000 description 10
• 102000039446 nucleic acids Human genes 0.000 description 10
• 108020004707 nucleic acids Proteins 0.000 description 10
• 150000007523 nucleic acids Chemical class 0.000 description 10
• 239000000047 product Substances 0.000 description 10
• 239000000758 substrate Substances 0.000 description 10
• 230000001225 therapeutic effect Effects 0.000 description 10
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 9
• 208000027418 Wounds and injury Diseases 0.000 description 9
• 230000002159 abnormal effect Effects 0.000 description 9
• 238000013459 approach Methods 0.000 description 9
• 238000012875 competitive assay Methods 0.000 description 9
• 230000008021 deposition Effects 0.000 description 9
• 238000003745 diagnosis Methods 0.000 description 9
• 201000001474 proteinuria Diseases 0.000 description 9
• 235000002639 sodium chloride Nutrition 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 210000001519 tissue Anatomy 0.000 description 9
• 210000004881 tumor cell Anatomy 0.000 description 9
• 206010006187 Breast cancer Diseases 0.000 description 8
• 208000026310 Breast neoplasm Diseases 0.000 description 8
• 102000004190 Enzymes Human genes 0.000 description 8
• 108090000790 Enzymes Proteins 0.000 description 8
• 238000009825 accumulation Methods 0.000 description 8
• 238000012217 deletion Methods 0.000 description 8
• 230000037430 deletion Effects 0.000 description 8
• 208000033679 diabetic kidney disease Diseases 0.000 description 8
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
• 229940088598 enzyme Drugs 0.000 description 8
• 230000028993 immune response Effects 0.000 description 8
• 230000002401 inhibitory effect Effects 0.000 description 8
• 208000017169 kidney disease Diseases 0.000 description 8
• 239000002773 nucleotide Substances 0.000 description 8
• 125000003729 nucleotide group Chemical group 0.000 description 8
• 239000002953 phosphate buffered saline Substances 0.000 description 8
• 230000001105 regulatory effect Effects 0.000 description 8
• 239000011780 sodium chloride Substances 0.000 description 8
• 239000002904 solvent Substances 0.000 description 8
• 210000002700 urine Anatomy 0.000 description 8
• 239000011534 wash buffer Substances 0.000 description 8
• 238000005406 washing Methods 0.000 description 8
• 208000019693 Lung disease Diseases 0.000 description 7
• 241000699670 Mus sp. Species 0.000 description 7
• 108091034117 Oligonucleotide Proteins 0.000 description 7
• 206010052428 Wound Diseases 0.000 description 7
• 239000012491 analyte Substances 0.000 description 7
• 230000005847 immunogenicity Effects 0.000 description 7
• 230000003993 interaction Effects 0.000 description 7
• 239000011159 matrix material Substances 0.000 description 7
• 230000009401 metastasis Effects 0.000 description 7
• 239000012071 phase Substances 0.000 description 7
• 238000000746 purification Methods 0.000 description 7
• 238000012552 review Methods 0.000 description 7
• 206010039073 rheumatoid arthritis Diseases 0.000 description 7
• 230000037390 scarring Effects 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
• 108091026890 Coding region Proteins 0.000 description 6
• 108020004414 DNA Proteins 0.000 description 6
• 108090000144 Human Proteins Proteins 0.000 description 6
• 102000003839 Human Proteins Human genes 0.000 description 6
• 206010060862 Prostate cancer Diseases 0.000 description 6
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 238000010790 dilution Methods 0.000 description 6
• 239000012895 dilution Substances 0.000 description 6
• 239000002552 dosage form Substances 0.000 description 6
• 230000004927 fusion Effects 0.000 description 6
• 230000003463 hyperproliferative effect Effects 0.000 description 6
• 230000000977 initiatory effect Effects 0.000 description 6
• 238000003780 insertion Methods 0.000 description 6
• 230000037431 insertion Effects 0.000 description 6
• 238000002703 mutagenesis Methods 0.000 description 6
• 231100000350 mutagenesis Toxicity 0.000 description 6
• 230000036963 noncompetitive effect Effects 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 238000012216 screening Methods 0.000 description 6
• 210000003491 skin Anatomy 0.000 description 6
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
• 238000012270 DNA recombination Methods 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 239000004471 Glycine Substances 0.000 description 5
• 241001529936 Murinae Species 0.000 description 5
• 241000288906 Primates Species 0.000 description 5
• 239000004365 Protease Substances 0.000 description 5
• 241000700605 Viruses Species 0.000 description 5
• 230000005856 abnormality Effects 0.000 description 5
• 238000001994 activation Methods 0.000 description 5
• QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 5
• 239000005557 antagonist Substances 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 229940098773 bovine serum albumin Drugs 0.000 description 5
• 210000004556 brain Anatomy 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• 238000007385 chemical modification Methods 0.000 description 5
• 208000019425 cirrhosis of liver Diseases 0.000 description 5
• 238000003776 cleavage reaction Methods 0.000 description 5
• 239000011248 coating agent Substances 0.000 description 5
• 238000000576 coating method Methods 0.000 description 5
• 230000002860 competitive effect Effects 0.000 description 5
• 231100000673 dose–response relationship Toxicity 0.000 description 5
• 230000005714 functional activity Effects 0.000 description 5
• 229960002449 glycine Drugs 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 230000002163 immunogen Effects 0.000 description 5
• 239000004615 ingredient Substances 0.000 description 5
• 239000003112 inhibitor Substances 0.000 description 5
• 238000001990 intravenous administration Methods 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 210000000651 myofibroblast Anatomy 0.000 description 5
• 210000000056 organ Anatomy 0.000 description 5
• 239000008055 phosphate buffer solution Substances 0.000 description 5
• -1 polypropylene Polymers 0.000 description 5
• 238000010837 poor prognosis Methods 0.000 description 5
• 229910052700 potassium Inorganic materials 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 238000012545 processing Methods 0.000 description 5
• 208000005069 pulmonary fibrosis Diseases 0.000 description 5
• 201000002793 renal fibrosis Diseases 0.000 description 5
• 230000007017 scission Effects 0.000 description 5
• 238000000926 separation method Methods 0.000 description 5
• 238000003860 storage Methods 0.000 description 5
• 230000009261 transgenic effect Effects 0.000 description 5
• 230000014616 translation Effects 0.000 description 5
• 201000004384 Alopecia Diseases 0.000 description 4
• 206010019668 Hepatic fibrosis Diseases 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• 206010061309 Neoplasm progression Diseases 0.000 description 4
• 102000057297 Pepsin A Human genes 0.000 description 4
• 108090000284 Pepsin A Proteins 0.000 description 4
• 102000035195 Peptidases Human genes 0.000 description 4
• 108091005804 Peptidases Proteins 0.000 description 4
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 230000006907 apoptotic process Effects 0.000 description 4
• 210000001367 artery Anatomy 0.000 description 4
• 239000012911 assay medium Substances 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 230000009137 competitive binding Effects 0.000 description 4
• 239000002299 complementary DNA Substances 0.000 description 4
• 230000002596 correlated effect Effects 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• 206010061989 glomerulosclerosis Diseases 0.000 description 4
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
• 230000002440 hepatic effect Effects 0.000 description 4
• 210000003494 hepatocyte Anatomy 0.000 description 4
• 238000004128 high performance liquid chromatography Methods 0.000 description 4
• 210000004408 hybridoma Anatomy 0.000 description 4
• 206010020718 hyperplasia Diseases 0.000 description 4
• 229940072221 immunoglobulins Drugs 0.000 description 4
• 230000006872 improvement Effects 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• 230000009545 invasion Effects 0.000 description 4
• 238000002372 labelling Methods 0.000 description 4
• 230000003211 malignant effect Effects 0.000 description 4
• 210000004962 mammalian cell Anatomy 0.000 description 4
• 238000013507 mapping Methods 0.000 description 4
• 210000004379 membrane Anatomy 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 210000003584 mesangial cell Anatomy 0.000 description 4
• 108020004999 messenger RNA Proteins 0.000 description 4
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
• 230000007935 neutral effect Effects 0.000 description 4
• 230000003287 optical effect Effects 0.000 description 4
• 230000001575 pathological effect Effects 0.000 description 4
• 229940111202 pepsin Drugs 0.000 description 4
• 239000000546 pharmaceutical excipient Substances 0.000 description 4
• 238000003127 radioimmunoassay Methods 0.000 description 4
• 239000011541 reaction mixture Substances 0.000 description 4
• 238000003259 recombinant expression Methods 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 238000001356 surgical procedure Methods 0.000 description 4
• 238000013518 transcription Methods 0.000 description 4
• 230000035897 transcription Effects 0.000 description 4
• 238000002054 transplantation Methods 0.000 description 4
• 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 4
• 230000005751 tumor progression Effects 0.000 description 4
• 241000701161 unidentified adenovirus Species 0.000 description 4
• 230000003612 virological effect Effects 0.000 description 4
• 230000029663 wound healing Effects 0.000 description 4
• 229910052727 yttrium Inorganic materials 0.000 description 4
• VPRHEJGLNUDEEH-LWILDLIXSA-N 2-[[(1r,2s,4as,8as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]cyclohexa-2,5-diene-1,4-dione Chemical compound C([C@@]1(C)[C@H]2[C@](C(=CCC2)C)(C)CC[C@@H]1C)C1=CC(=O)C=CC1=O VPRHEJGLNUDEEH-LWILDLIXSA-N 0.000 description 3
• IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 3
• 101150000157 ARHGEF1 gene Proteins 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 102000008186 Collagen Human genes 0.000 description 3
• 108010035532 Collagen Proteins 0.000 description 3
• 108091035707 Consensus sequence Proteins 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 206010020880 Hypertrophy Diseases 0.000 description 3
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• 241000699660 Mus musculus Species 0.000 description 3
• 206010029113 Neovascularisation Diseases 0.000 description 3
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 102100037678 Protein CEI Human genes 0.000 description 3
• 206010037549 Purpura Diseases 0.000 description 3
• 241001672981 Purpura Species 0.000 description 3
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
• 210000001744 T-lymphocyte Anatomy 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 239000007983 Tris buffer Substances 0.000 description 3
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 3
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 230000002776 aggregation Effects 0.000 description 3
• 238000004220 aggregation Methods 0.000 description 3
• 150000001412 amines Chemical class 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 230000000890 antigenic effect Effects 0.000 description 3
• 208000006673 asthma Diseases 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 239000011324 bead Substances 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• 238000001516 cell proliferation assay Methods 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 238000004140 cleaning Methods 0.000 description 3
• 229920001436 collagen Polymers 0.000 description 3
• 230000000295 complement effect Effects 0.000 description 3
• 230000000536 complexating effect Effects 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 239000003599 detergent Substances 0.000 description 3
• 206010012601 diabetes mellitus Diseases 0.000 description 3
• 239000012636 effector Substances 0.000 description 3
• 238000005516 engineering process Methods 0.000 description 3
• 230000002068 genetic effect Effects 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 229960001269 glycine hydrochloride Drugs 0.000 description 3
• 230000013595 glycosylation Effects 0.000 description 3
• 238000006206 glycosylation reaction Methods 0.000 description 3
• 230000009931 harmful effect Effects 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 230000001939 inductive effect Effects 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• 238000000506 liquid--solid chromatography Methods 0.000 description 3
• 101150055452 lsc gene Proteins 0.000 description 3
• 210000005075 mammary gland Anatomy 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 230000002503 metabolic effect Effects 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 238000012986 modification Methods 0.000 description 3
• 210000003739 neck Anatomy 0.000 description 3
• 238000006386 neutralization reaction Methods 0.000 description 3
• 210000001672 ovary Anatomy 0.000 description 3
• 238000002823 phage display Methods 0.000 description 3
• 230000026731 phosphorylation Effects 0.000 description 3
• 238000006366 phosphorylation reaction Methods 0.000 description 3
• 239000004033 plastic Substances 0.000 description 3
• 229920003023 plastic Polymers 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• 238000001556 precipitation Methods 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• 230000002062 proliferating effect Effects 0.000 description 3
• 230000006337 proteolytic cleavage Effects 0.000 description 3
• 230000005855 radiation Effects 0.000 description 3
• 238000001959 radiotherapy Methods 0.000 description 3
• 238000010188 recombinant method Methods 0.000 description 3
• 230000008929 regeneration Effects 0.000 description 3
• 238000011069 regeneration method Methods 0.000 description 3
• 201000000306 sarcoidosis Diseases 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 239000007790 solid phase Substances 0.000 description 3
• 241000894007 species Species 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 230000008719 thickening Effects 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 238000013519 translation Methods 0.000 description 3
• 238000011269 treatment regimen Methods 0.000 description 3
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
• 238000001262 western blot Methods 0.000 description 3
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
• PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 description 2
• 208000009304 Acute Kidney Injury Diseases 0.000 description 2
• 206010066728 Acute interstitial pneumonitis Diseases 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 108010006654 Bleomycin Proteins 0.000 description 2
• 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 2
• 206010006448 Bronchiolitis Diseases 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 108090000317 Chymotrypsin Proteins 0.000 description 2
• 108020004705 Codon Proteins 0.000 description 2
• 206010010356 Congenital anomaly Diseases 0.000 description 2
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
• 102000016359 Fibronectins Human genes 0.000 description 2
• 108010067306 Fibronectins Proteins 0.000 description 2
• 208000015872 Gaucher disease Diseases 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• 108010024636 Glutathione Proteins 0.000 description 2
• 235000010469 Glycine max Nutrition 0.000 description 2
• 108060003393 Granulin Proteins 0.000 description 2
• 208000031071 Hamman-Rich Syndrome Diseases 0.000 description 2
• 208000018565 Hemochromatosis Diseases 0.000 description 2
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
• 101000628693 Homo sapiens Serine/threonine-protein kinase 25 Proteins 0.000 description 2
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 206010023421 Kidney fibrosis Diseases 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
• 208000004554 Leishmaniasis Diseases 0.000 description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
• 108060001084 Luciferase Proteins 0.000 description 2
• 239000005089 Luciferase Substances 0.000 description 2
• 206010066453 Mesangioproliferative glomerulonephritis Diseases 0.000 description 2
• 101100182721 Mus musculus Ly6e gene Proteins 0.000 description 2
• 241000737052 Naso hexacanthus Species 0.000 description 2
• 108700026244 Open Reading Frames Proteins 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 208000008558 Osteophyte Diseases 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• 108010033276 Peptide Fragments Proteins 0.000 description 2
• 102000007079 Peptide Fragments Human genes 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 101710182846 Polyhedrin Proteins 0.000 description 2
• 239000004743 Polypropylene Substances 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• 208000033626 Renal failure acute Diseases 0.000 description 2
• 206010038934 Retinopathy proliferative Diseases 0.000 description 2
• 101150060303 SOK2 gene Proteins 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• 229920002684 Sepharose Polymers 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 102100026737 Serine/threonine-protein kinase 25 Human genes 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
• 108091081024 Start codon Proteins 0.000 description 2
• 201000009594 Systemic Scleroderma Diseases 0.000 description 2
• 206010042953 Systemic sclerosis Diseases 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 239000004473 Threonine Substances 0.000 description 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
• PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
• 210000001015 abdomen Anatomy 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 229960000583 acetic acid Drugs 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 201000004073 acute interstitial pneumonia Diseases 0.000 description 2
• 201000011040 acute kidney failure Diseases 0.000 description 2
• 208000012998 acute renal failure Diseases 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 238000007818 agglutination assay Methods 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 230000003321 amplification Effects 0.000 description 2
• 239000003708 ampul Substances 0.000 description 2
• 239000003098 androgen Substances 0.000 description 2
• 238000000137 annealing Methods 0.000 description 2
• 230000009833 antibody interaction Effects 0.000 description 2
• 230000009831 antigen interaction Effects 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 235000003704 aspartic acid Nutrition 0.000 description 2
• 230000003143 atherosclerotic effect Effects 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
• 210000003445 biliary tract Anatomy 0.000 description 2
• 230000008827 biological function Effects 0.000 description 2
• 239000012472 biological sample Substances 0.000 description 2
• 229960001561 bleomycin Drugs 0.000 description 2
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 239000007853 buffer solution Substances 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 230000009400 cancer invasion Effects 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• WLNARFZDISHUGS-MIXBDBMTSA-N cholesteryl hemisuccinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 WLNARFZDISHUGS-MIXBDBMTSA-N 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 229960002376 chymotrypsin Drugs 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 238000010668 complexation reaction Methods 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 208000029078 coronary artery disease Diseases 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 229910052805 deuterium Inorganic materials 0.000 description 2
• 238000000502 dialysis Methods 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 238000009792 diffusion process Methods 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
• 229960004082 doxycycline hydrochloride Drugs 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 238000010828 elution Methods 0.000 description 2
• 230000013020 embryo development Effects 0.000 description 2
• 208000028208 end stage renal disease Diseases 0.000 description 2
• 201000000523 end stage renal failure Diseases 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• 208000030533 eye disease Diseases 0.000 description 2
• 230000002349 favourable effect Effects 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
• 235000019253 formic acid Nutrition 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• 238000012817 gel-diffusion technique Methods 0.000 description 2
• 238000007429 general method Methods 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 235000004554 glutamine Nutrition 0.000 description 2
• 229960003180 glutathione Drugs 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 230000003676 hair loss Effects 0.000 description 2
• 210000003128 head Anatomy 0.000 description 2
• 210000000777 hematopoietic system Anatomy 0.000 description 2
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 230000013632 homeostatic process Effects 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 229960002591 hydroxyproline Drugs 0.000 description 2
• 230000001969 hypertrophic effect Effects 0.000 description 2
• 230000037451 immune surveillance Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 230000000951 immunodiffusion Effects 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 239000000411 inducer Substances 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• 210000002510 keratinocyte Anatomy 0.000 description 2
• 210000003292 kidney cell Anatomy 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 208000019423 liver disease Diseases 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 231100000219 mutagenic Toxicity 0.000 description 2
• 230000003505 mutagenic effect Effects 0.000 description 2
• 210000000822 natural killer cell Anatomy 0.000 description 2
• 201000008383 nephritis Diseases 0.000 description 2
• 210000000885 nephron Anatomy 0.000 description 2
• 201000009925 nephrosclerosis Diseases 0.000 description 2
• 238000003199 nucleic acid amplification method Methods 0.000 description 2
• 230000008520 organization Effects 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• 102000013415 peroxidase activity proteins Human genes 0.000 description 2
• 108040007629 peroxidase activity proteins Proteins 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 230000004962 physiological condition Effects 0.000 description 2
• 230000036470 plasma concentration Effects 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• 239000013259 porous coordination polymer Substances 0.000 description 2
• 230000001376 precipitating effect Effects 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 235000019419 proteases Nutrition 0.000 description 2
• 238000001742 protein purification Methods 0.000 description 2
• 230000002797 proteolythic effect Effects 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 239000012857 radioactive material Substances 0.000 description 2
• 230000006798 recombination Effects 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 210000002345 respiratory system Anatomy 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 150000003839 salts Chemical group 0.000 description 2
• 231100000241 scar Toxicity 0.000 description 2
• 238000007423 screening assay Methods 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 235000004400 serine Nutrition 0.000 description 2
• 238000001542 size-exclusion chromatography Methods 0.000 description 2
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 238000013222 sprague-dawley male rat Methods 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 239000008223 sterile water Substances 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 230000009897 systematic effect Effects 0.000 description 2
• 229960001603 tamoxifen Drugs 0.000 description 2
• 210000001550 testis Anatomy 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 235000008521 threonine Nutrition 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 238000011830 transgenic mouse model Methods 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 235000002374 tyrosine Nutrition 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 239000004474 valine Substances 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
• CJVFIJXEPCVCTK-LWMBYGOMSA-N (2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)C(C)C)C(C)C CJVFIJXEPCVCTK-LWMBYGOMSA-N 0.000 description 1
• YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
• NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 description 1
• VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• 101150084750 1 gene Proteins 0.000 description 1
• GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
• CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
• QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
• TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• 208000007122 AIDS-Associated Nephropathy Diseases 0.000 description 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 241000766754 Agra Species 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
• 208000037259 Amyloid Plaque Diseases 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 206010059245 Angiopathy Diseases 0.000 description 1
• 102000012936 Angiostatins Human genes 0.000 description 1
• 108010079709 Angiostatins Proteins 0.000 description 1
• 101100273858 Anopheles gambiae CecB gene Proteins 0.000 description 1
• 241000272517 Anseriformes Species 0.000 description 1
• 208000033116 Asbestos intoxication Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 102220518628 Baculoviral IAP repeat-containing protein 6_T47E_mutation Human genes 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000007257 Budd-Chiari syndrome Diseases 0.000 description 1
• 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
• 108091007914 CDKs Proteins 0.000 description 1
• 101100324465 Caenorhabditis elegans arr-1 gene Proteins 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 206010007558 Cardiac failure chronic Diseases 0.000 description 1
• 208000024172 Cardiovascular disease Diseases 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 241000701489 Cauliflower mosaic virus Species 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 208000032544 Cicatrix Diseases 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 102000012422 Collagen Type I Human genes 0.000 description 1
• 108010022452 Collagen Type I Proteins 0.000 description 1
• 208000029147 Collagen-vascular disease Diseases 0.000 description 1
• 108060005980 Collagenase Proteins 0.000 description 1
• 102000029816 Collagenase Human genes 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 206010056533 Congenital hepatic fibrosis Diseases 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 102000003909 Cyclin E Human genes 0.000 description 1
• 108090000257 Cyclin E Proteins 0.000 description 1
• 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 1
• 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
• 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
• 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• 102100035429 Cystathionine gamma-lyase Human genes 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 102000012410 DNA Ligases Human genes 0.000 description 1
• 108010061982 DNA Ligases Proteins 0.000 description 1
• 230000004543 DNA replication Effects 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 201000003066 Diffuse Scleroderma Diseases 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 101100533231 Drosophila melanogaster Jon99Ciii gene Proteins 0.000 description 1
• 101100059603 Drosophila virilis Cec3 gene Proteins 0.000 description 1
• 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 101150104370 ERC1 gene Proteins 0.000 description 1
• 108010000912 Egg Proteins Proteins 0.000 description 1
• 102000002322 Egg Proteins Human genes 0.000 description 1
• 206010014561 Emphysema Diseases 0.000 description 1
• 208000037487 Endotoxemia Diseases 0.000 description 1
• 241000702224 Enterobacteria phage M13 Species 0.000 description 1
• 101710104662 Enterotoxin type C-3 Proteins 0.000 description 1
• 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
• 241000283074 Equus asinus Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 208000010228 Erectile Dysfunction Diseases 0.000 description 1
• 241000402754 Erythranthe moschata Species 0.000 description 1
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
• 208000036566 Erythroleukaemia Diseases 0.000 description 1
• 102100030844 Exocyst complex component 1 Human genes 0.000 description 1
• 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
• 206010073306 Exposure to radiation Diseases 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 208000004930 Fatty Liver Diseases 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• 206010072104 Fructose intolerance Diseases 0.000 description 1
• 208000027472 Galactosemias Diseases 0.000 description 1
• 102100040837 Galactoside alpha-(1,2)-fucosyltransferase 2 Human genes 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 206010056740 Genital discharge Diseases 0.000 description 1
• 206010018341 Gliosis Diseases 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 229920002527 Glycogen Polymers 0.000 description 1
• 208000002927 Hamartoma Diseases 0.000 description 1
• 101710154606 Hemagglutinin Proteins 0.000 description 1
• 230000010556 Heparin Binding Activity Effects 0.000 description 1
• 206010019799 Hepatitis viral Diseases 0.000 description 1
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
• 206010019878 Hereditary fructose intolerance Diseases 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000893710 Homo sapiens Galactoside alpha-(1,2)-fucosyltransferase 2 Proteins 0.000 description 1
• 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
• 208000019758 Hypergammaglobulinemia Diseases 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010020915 Hypervitaminosis Diseases 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 108020005350 Initiator Codon Proteins 0.000 description 1
• 102100023915 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102100039897 Interleukin-5 Human genes 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 208000029523 Interstitial Lung disease Diseases 0.000 description 1
• 206010065973 Iron Overload Diseases 0.000 description 1
• PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• XIGSAGMEBXLVJJ-YFKPBYRVSA-N L-homocitrulline Chemical compound NC(=O)NCCCC[C@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 102000007547 Laminin Human genes 0.000 description 1
• 108010085895 Laminin Proteins 0.000 description 1
• 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
• 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 239000000232 Lipid Bilayer Substances 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 102000008072 Lymphokines Human genes 0.000 description 1
• 108010074338 Lymphokines Proteins 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 102100026459 POU domain, class 3, transcription factor 2 Human genes 0.000 description 1
• 101710133394 POU domain, class 3, transcription factor 2 Proteins 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 102000016387 Pancreatic elastase Human genes 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 208000002774 Paraproteinemias Diseases 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 101710137908 Pepsin-2 Proteins 0.000 description 1
• 208000020547 Peroxisomal disease Diseases 0.000 description 1
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
• 108010001014 Plasminogen Activators Proteins 0.000 description 1
• 102000001938 Plasminogen Activators Human genes 0.000 description 1
• 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 108010076039 Polyproteins Proteins 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 201000009454 Portal vein thrombosis Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 229910052774 Proactinium Inorganic materials 0.000 description 1
• 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 101710176177 Protein A56 Proteins 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 208000003782 Raynaud disease Diseases 0.000 description 1
• 208000012322 Raynaud phenomenon Diseases 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 206010038546 Renal vasculitis Diseases 0.000 description 1
• 241000702263 Reovirus sp. Species 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 206010038687 Respiratory distress Diseases 0.000 description 1
• 108050002653 Retinoblastoma protein Proteins 0.000 description 1
• 102220469221 S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase TYW1B_E18A_mutation Human genes 0.000 description 1
• 101150052146 SER2 gene Proteins 0.000 description 1
• 101150007309 SOK3 gene Proteins 0.000 description 1
• 101100263989 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MTC5 gene Proteins 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 244000000231 Sesamum indicum Species 0.000 description 1
• 235000003434 Sesamum indicum Nutrition 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 101000882403 Staphylococcus aureus Enterotoxin type C-2 Proteins 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 108700023707 TUG1 Proteins 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• IOYNQIMAUDJVEI-BMVIKAAMSA-N Tepraloxydim Chemical group C1C(=O)C(C(=N/OC\C=C\Cl)/CC)=C(O)CC1C1CCOCC1 IOYNQIMAUDJVEI-BMVIKAAMSA-N 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 102100029530 Thyrotropin subunit beta Human genes 0.000 description 1
• 241000723873 Tobacco mosaic virus Species 0.000 description 1
• JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
• 206010070863 Toxicity to various agents Diseases 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• 101710117056 Trimethylamine corrinoid protein 2 Proteins 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 206010064390 Tumour invasion Diseases 0.000 description 1
• YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 208000012346 Venoocclusive disease Diseases 0.000 description 1
• 208000012634 Venoocclusive liver disease Diseases 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 208000018839 Wilson disease Diseases 0.000 description 1
• 201000004525 Zellweger Syndrome Diseases 0.000 description 1
• 208000036813 Zellweger spectrum disease Diseases 0.000 description 1
• INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
• HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
• 210000003815 abdominal wall Anatomy 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 239000002390 adhesive tape Substances 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 231100000360 alopecia Toxicity 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 235000020616 amino acid formula Nutrition 0.000 description 1
• 229960005260 amiodarone Drugs 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 206010068168 androgenetic alopecia Diseases 0.000 description 1
• 201000002996 androgenic alopecia Diseases 0.000 description 1
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 238000002399 angioplasty Methods 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 238000011319 anticancer therapy Methods 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 206010003441 asbestosis Diseases 0.000 description 1
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 208000037875 astrocytosis Diseases 0.000 description 1
• 230000007341 astrogliosis Effects 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000003305 autocrine Effects 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000006470 autoimmune attack Effects 0.000 description 1
• 230000006472 autoimmune response Effects 0.000 description 1
• 150000001540 azides Chemical class 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 210000004082 barrier epithelial cell Anatomy 0.000 description 1
• 238000005452 bending Methods 0.000 description 1
• GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
• 108010068678 beta Subunit Thyrotropin Proteins 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• 229940064804 betadine Drugs 0.000 description 1
• 210000000013 bile duct Anatomy 0.000 description 1
• 238000013248 bile duct ligation model Methods 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 239000012620 biological material Substances 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 238000004820 blood count Methods 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 230000014461 bone development Effects 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 239000008366 buffered solution Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 244000309466 calf Species 0.000 description 1
• 238000002619 cancer immunotherapy Methods 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 231100000315 carcinogenic Toxicity 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 230000011748 cell maturation Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 239000005081 chemiluminescent agent Substances 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
• 229960001076 chlorpromazine Drugs 0.000 description 1
• 201000002816 chronic venous insufficiency Diseases 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 101150044072 cn gene Proteins 0.000 description 1
• 229960002424 collagenase Drugs 0.000 description 1
• 238000004737 colorimetric analysis Methods 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 210000001953 common bile duct Anatomy 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 239000003636 conditioned culture medium Substances 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 239000013068 control sample Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 239000013256 coordination polymer Substances 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 238000007887 coronary angioplasty Methods 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
• 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 238000005034 decoration Methods 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 238000003795 desorption Methods 0.000 description 1
• 230000009547 development abnormality Effects 0.000 description 1
• 239000000032 diagnostic agent Substances 0.000 description 1
• 229940039227 diagnostic agent Drugs 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 210000002249 digestive system Anatomy 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 238000011827 double-transgenic mouse model Methods 0.000 description 1
• 239000003651 drinking water Substances 0.000 description 1
• 235000020188 drinking water Nutrition 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 235000014103 egg white Nutrition 0.000 description 1
• 210000000969 egg white Anatomy 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 210000000750 endocrine system Anatomy 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 208000003401 eosinophilic granuloma Diseases 0.000 description 1
• 230000004890 epithelial barrier function Effects 0.000 description 1
• 230000008029 eradication Effects 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• AWYNYGDVTNSMIS-UHFFFAOYSA-N ethanamine;ethanol Chemical compound CCN.CCO AWYNYGDVTNSMIS-UHFFFAOYSA-N 0.000 description 1
• ISLJZDYAPAUORR-UHFFFAOYSA-N ethyl n-[2-[(5-nitrothiophene-2-carbonyl)amino]thiophene-3-carbonyl]carbamate Chemical compound C1=CSC(NC(=O)C=2SC(=CC=2)[N+]([O-])=O)=C1C(=O)NC(=O)OCC ISLJZDYAPAUORR-UHFFFAOYSA-N 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 238000013213 extrapolation Methods 0.000 description 1
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
• 210000001508 eye Anatomy 0.000 description 1
• 239000012894 fetal calf serum Substances 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 230000003352 fibrogenic effect Effects 0.000 description 1
• 230000000893 fibroproliferative effect Effects 0.000 description 1
• 230000009795 fibrotic process Effects 0.000 description 1
• 230000009791 fibrotic reaction Effects 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 1
• 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 210000001061 forehead Anatomy 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
• 229940044627 gamma-interferon Drugs 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000005227 gel permeation chromatography Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 239000012362 glacial acetic acid Substances 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 230000001434 glomerular Effects 0.000 description 1
• 210000001707 glomerular endothelial cell Anatomy 0.000 description 1
• 239000003292 glue Substances 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 229940096919 glycogen Drugs 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 230000009422 growth inhibiting effect Effects 0.000 description 1
• 230000009036 growth inhibition Effects 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 230000035931 haemagglutination Effects 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 230000003779 hair growth Effects 0.000 description 1
• 208000024963 hair loss Diseases 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 230000003862 health status Effects 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 230000004730 hepatocarcinogenesis Effects 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• 201000006846 hereditary fructose intolerance syndrome Diseases 0.000 description 1
• 201000008298 histiocytosis Diseases 0.000 description 1
• 239000000710 homodimer Substances 0.000 description 1
• 238000009396 hybridization Methods 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
• 125000001841 imino group Chemical group [H]N=* 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 238000010166 immunofluorescence Methods 0.000 description 1
• 230000009851 immunogenic response Effects 0.000 description 1
• 229940099472 immunoglobulin a Drugs 0.000 description 1
• 238000010324 immunological assay Methods 0.000 description 1
• 239000012133 immunoprecipitate Substances 0.000 description 1
• 239000003547 immunosorbent Substances 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 201000001881 impotence Diseases 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 229940060367 inert ingredients Drugs 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229940100602 interleukin-5 Drugs 0.000 description 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 235000014413 iron hydroxide Nutrition 0.000 description 1
• NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical class [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 229960002725 isoflurane Drugs 0.000 description 1
• 208000014861 isolated congenital hepatic fibrosis Diseases 0.000 description 1
• 229960003350 isoniazid Drugs 0.000 description 1
• QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 208000011379 keloid formation Diseases 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 210000000867 larynx Anatomy 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 230000037356 lipid metabolism Effects 0.000 description 1
• 230000029226 lipidation Effects 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000002502 liposome Substances 0.000 description 1
• 239000007791 liquid phase Substances 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 231100000832 liver cell necrosis Toxicity 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 230000001589 lymphoproliferative effect Effects 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 201000000564 macroglobulinemia Diseases 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 150000001455 metallic ions Chemical class 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 238000010208 microarray analysis Methods 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 230000027939 micturition Effects 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 230000003020 moisturizing effect Effects 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 239000000178 monomer Substances 0.000 description 1
• 238000002887 multiple sequence alignment Methods 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
• ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 230000002956 necrotizing effect Effects 0.000 description 1
• 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
• 230000030505 negative regulation of chemotaxis Effects 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 238000011580 nude mouse model Methods 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 230000033667 organ regeneration Effects 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• SJDACOMXKWHBOW-UHFFFAOYSA-N oxyphenisatine Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2NC1=O SJDACOMXKWHBOW-UHFFFAOYSA-N 0.000 description 1
• 229960003241 oxyphenisatine Drugs 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 229940124583 pain medication Drugs 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 230000003071 parasitic effect Effects 0.000 description 1
• 210000002990 parathyroid gland Anatomy 0.000 description 1
• 210000003681 parotid gland Anatomy 0.000 description 1
• 231100000915 pathological change Toxicity 0.000 description 1
• 230000036285 pathological change Effects 0.000 description 1
• 230000001991 pathophysiological effect Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• 210000004197 pelvis Anatomy 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 210000005164 penile vein Anatomy 0.000 description 1
• 230000007030 peptide scission Effects 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 210000004303 peritoneum Anatomy 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 210000001539 phagocyte Anatomy 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000001817 pituitary effect Effects 0.000 description 1
• 229940127126 plasminogen activator Drugs 0.000 description 1
• 230000004983 pleiotropic effect Effects 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 201000006038 polycystic kidney disease 4 Diseases 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 239000004800 polyvinyl chloride Substances 0.000 description 1
• 229920000915 polyvinyl chloride Polymers 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 239000004224 potassium gluconate Substances 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 201000011461 pre-eclampsia Diseases 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000000861 pro-apoptotic effect Effects 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
• 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000009979 protective mechanism Effects 0.000 description 1
• 230000009145 protein modification Effects 0.000 description 1
• 239000012460 protein solution Substances 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 238000004451 qualitative analysis Methods 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 238000011552 rat model Methods 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
• 230000027272 reproductive process Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 235000002020 sage Nutrition 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 230000036573 scar formation Effects 0.000 description 1
• 230000037387 scars Effects 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 238000011896 sensitive detection Methods 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 206010040882 skin lesion Diseases 0.000 description 1
• 231100000444 skin lesion Toxicity 0.000 description 1
• 201000010017 slate pneumoconiosis Diseases 0.000 description 1
• 238000010583 slow cooling Methods 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 210000004872 soft tissue Anatomy 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 235000000891 standard diet Nutrition 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008227 sterile water for injection Substances 0.000 description 1
• 239000000021 stimulant Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 210000002536 stromal cell Anatomy 0.000 description 1
• 108091007196 stromelysin Proteins 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 238000007460 surgical drainage Methods 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 210000001179 synovial fluid Anatomy 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 238000004448 titration Methods 0.000 description 1
• 229960005371 tolbutamide Drugs 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 239000002753 trypsin inhibitor Substances 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 230000005748 tumor development Effects 0.000 description 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
• MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 201000011296 tyrosinemia Diseases 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 210000001635 urinary tract Anatomy 0.000 description 1
• 210000002229 urogenital system Anatomy 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 230000006459 vascular development Effects 0.000 description 1
• 230000006492 vascular dysfunction Effects 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 201000002282 venous insufficiency Diseases 0.000 description 1
• 230000002861 ventricular Effects 0.000 description 1
• 201000001862 viral hepatitis Diseases 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 238000011179 visual inspection Methods 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 239000012224 working solution Substances 0.000 description 1
• CZPRKINNVBONSF-UHFFFAOYSA-M zinc;dioxido(oxo)phosphanium Chemical compound [Zn+2].[O-][P+]([O-])=O CZPRKINNVBONSF-UHFFFAOYSA-M 0.000 description 1